Birgit Leimer News Today

During Ramadan, adult Muslims – both men and women and some children – abstain from food and drinks during daylight hours.

Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH FDAs Fast Track Designation for the GLP-1/glucagon dual agonist underscores the urgent need for new treatment options to fulfill the unmet medical needs of people affected by NASH. Boehringer Ingelheims focus on the development of next generation NASH treatments builds on its strong track record of bringing new therapies to people with cardiometabolic diseases. Boehringer Ingelheim ...

New studies mark an important advancement of Boehringer Ingelheim's cardiometabolic focus areas obesity and NASH. The GLP-1/glucagon dual agonist BI 456906 may offer important benefits on